BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MediVet-America: Vet-Stem Misleads Veterinarians and Consumers Over Animal Stem Cell Technology


3/24/2011 8:16:49 AM

NICHOLASVILLE, Ky., March 23, 2011 /PRNewswire/ -- Faced with the next generation of animal stem cell technology that enables consumers to treat their animals at almost half the cost with MediVet-America's advanced stem cell therapy, Vet-Stem, Inc. has taken to misleading statements that muddy the waters, according to MediVet-America CEO Jeremy Delk. Vet-Stem, in a cleverly worded news release entitled "Confirmation of Vet-Stem Exclusive Rights to Veterinary Use of Adipose Stem Cells," has created confusion as to what this means for veterinarians wanting to practice best medicine and utilize the latest technologies available.

The March 16, 2011 release implies a recent court victory favoring Vet-Stem. In fact, it is an excerpt from an article pertaining to a court case from June 19, 2008, concerning a ruling on a dispute between a group of researchers and universities regarding ownership of a patent filed nearly a decade ago, Delk said. This portfolio is not currently in dispute by any relevant parties, including the publicly-listed company Cytori that lost the case.

The news release states that, "Artecel, Inc., is the human stem cell company that holds all of the rights to this patent portfolio" (referring to Patent 231 and the rest of portfolio). This excerpt refers to these specific patents only, according to Delk. This essentially is a dispute between a few universities and researchers, not over the use of all stem cells as implied in the title of the release. Vet-Stem makes the ambiguous claim that no other company can use adipose derived stem cells, including Cytori, as well as the hundreds of other companies operating in the U.S. and abroad.

"MediVet America's mission is to develop the best technologies and procedures, allowing veterinarians to practice best medicine. Confusing consumers by using carefully-crafted news releases in an attempt to hold onto market share is unfortunate but expected," said Delk. "MediVet-America will continue to provide the latest advancements in stem cell technologies using its own intellectual property in order to help millions of animals suffering in pain from osteoarthritis and hip dysplasia."

A research and development firm as well as global leader in veterinary stem cell technology, MediVet provides innovative cell technology applications for the therapeutic care of animals. Headquartered in Nicholasville, Kentucky, MediVet-America develops advanced cellular kits and services for the treatment of Osteoarthritis and Degenerative Joint Disease.

www.MediVet-America.com

CONTACT: Jeremy Delk
MediVet-America
(859) 885-7111

SOURCE MediVet-America



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES